ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca and 3SBio side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZeneca3SBio
studies on the registry4,197107
open to participants now29846
phase 3 studies under way20011
reach primary completion within a year16816
programswith a study of their own in two years119+5 named only27

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZeneca3SBio
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

3SBio: 11 of its 27 programs at phase 1

  1. 3SC009phase 1
  2. existing formulations of 611phase 1
  3. HBT-708phase 1
  4. new formulations of 611phase 1
  5. SSGJ-709phase 1

and 6 more — sign in to see them all

41%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

3SBio: 11 of its 27 programs at phase 2

  1. Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705phase 2
  2. SSGJ-706phase 2
  3. SPGL008phase 2
  4. SSS17phase 2
  5. SSGJ-613phase 2

and 6 more — sign in to see them all

41%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

3SBio: 5 of its 27 programs at phase 3

  1. camtarkibartphase 3
  2. 608phase 3
  3. tivunatamigphase 3
  4. Clascoteronephase 3
  5. Minoxidilphase 3
19%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca61 readouts · 16 phase 3

AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion

  1. elecoglipronphase 3 · Nov 18 · NCT07723833
  2. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  3. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  4. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  5. durvalumabapproved, new study · Nov 30 · NCT07081633

and 1 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
3SBio11 readouts · 2 phase 3·

3SBio, Dec ’26: 5 programs whose next study reaches primary completion

  1. Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705phase 2 · Dec 0 · NCT06390774
  2. SSGJ-706phase 2 · Dec 0 · NCT07233850
  3. SSS55phase 1 · Dec 0 · NCT07058779
  4. SSS68phase 1 · Dec 0 · NCT07606976
  5. xeloxphase 2 · Dec 0 · NCT07233850

3SBio, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. 608phase 3 · Jan 14 · NCT07261644
·

3SBio, Mar ’27: 1 program whose next study reaches primary completion

  1. SSS59phase 1 · Mar 1 · NCT06944444
····

3SBio, Aug ’27: 2 programs whose next study reaches primary completion

  1. SSGJ-613phase 2 · Aug 11 · NCT07708181
  2. SSGJ-716phase 1 · Aug 29 · NCT07693738

3SBio, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. camtarkibartphase 3 · Sep 0 · NCT07767253
  2. SSGJ-709phase 1 · Sep 30 · NCT07016490
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

3SBio

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.

ConditionAstraZeneca3SBio
Carcinoma, Non-Small-Cell Lungboth · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 18 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 13 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

3SBio in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. tivunatamigphase 3
  2. SSGJ-706phase 2
  3. SPGL008phase 2
  4. xeloxphase 2

Their studies: 3SBio’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

AstraZeneca in Breast Neoplasms: 9 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 4 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

3SBio in Breast Neoplasms: 2 programs

  1. SSGJ-612phase 2
  2. HER2-targeted ADCphase 2

Their studies: 3SBio’s studies of Breast Neoplasms in search

Stomach Neoplasmsboth · compare here

3SBio in Stomach Neoplasms: 2 programs

  1. tivunatamigphase 3
  2. xeloxphase 2

Their studies: 3SBio’s studies of Stomach Neoplasms in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

3SBio in Pulmonary Disease, Chronic Obstructive: 1 program

  1. camtarkibartphase 3

Their studies: 3SBio’s studies of Pulmonary Disease, Chronic Obstructive in search

Neoplasmsboth · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Colorectal Neoplasmsboth · compare here

AstraZeneca in Colorectal Neoplasms: 2 programs

  1. Actinium-225phase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

3SBio in Colorectal Neoplasms: 3 programs

  1. tivunatamigphase 3
  2. SSGJ-706phase 2
  3. xeloxphase 2

Their studies: 3SBio’s studies of Colorectal Neoplasms in search

Dermatitis, Atopicboth · compare here

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

3SBio in Dermatitis, Atopic: 3 programs

  1. camtarkibartphase 3
  2. existing formulations of 611phase 1
  3. new formulations of 611phase 1

Their studies: 3SBio’s studies of Dermatitis, Atopic in search

Endometrial Neoplasmsboth · compare here

AstraZeneca in Endometrial Neoplasms: 3 programs

  1. datopotamab deruxtecanphase 3
  2. puxitatug samrotecanphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

3SBio in Endometrial Neoplasms: 1 program

  1. tivunatamigphase 3

Their studies: 3SBio’s studies of Endometrial Neoplasms in search

Lupus Erythematosus, Systemicboth · compare here

3SBio in Lupus Erythematosus, Systemic: 1 program

  1. 626phase 2

Their studies: 3SBio’s studies of Lupus Erythematosus, Systemic in search

Small Cell Lung Carcinomaboth · compare here

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

3SBio in Small Cell Lung Carcinoma: 1 program

  1. tivunatamigphase 3

Their studies: 3SBio’s studies of Small Cell Lung Carcinoma in search

Colitis, Ulcerativeboth · compare here

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

3SBio in Colitis, Ulcerative: 1 program

  1. 627phase 2

Their studies: 3SBio’s studies of Colitis, Ulcerative in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · 3SBio 6 of 27 programs (34 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).